Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
These findings suggest that there is a narrow window or ‘sweet spot’ of oncogenic RAS signalling conducive to tumour formation; too much leads to abortive processes like growth arrest, and too little ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results